A new study found that a novel mRNA-based therapy that targets a protein called RUNX1 may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR), a disease caused by a traumatic eye injury or surgery like a retinal detachment repair that currently lacks effective treatments other than additional surgical procedures. Since RUNX1 is active in other diseases, the researchers also hope in the future to apply their mRNA technique to treat other retinal conditions like wet age-related macular degeneration and diabetic retinopathy.
Geiger Mueller News Service